Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Suspended 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 3Gastrointestinal 3Dermatologic 3Breast 3Tumor-Agnostic 2Thoracic 2Sarcoma 2Lymphoid 2Gynecologic 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Ovarian Neoplasms 5Uterine Cervical Neoplasms 4Melanoma 3Fallopian Tube Neoplasms 3Vulvar Neoplasms 2Triple Negative Breast Neoplasms 2Seminoma 2Neoplasm Metastasis 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Acute 2Endometrial Neoplasms 2Congenital Abnormalities 2Carcinoma, Ovarian Epithelial 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Endometrioid 2Vaginal Neoplasms 1Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Testicular Neoplasms 1Teratoma, Testicular 1Teratoma 1Somatostatinoma 1Sarcoma 1Rare Diseases 1Pseudomyxoma Peritonei 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pheochromocytoma 1Perivascular Epithelioid Cell Neoplasms 1Peritoneal Neoplasms 1Parathyroid Neoplasms 1

Interventions

pembrolizumab 23Paclitaxel 14Cyclophosphamide 13Carboplatin 12Specimen Handling 10Magnetic Resonance Spectroscopy 10Biopsy 9fludarabine 8Nivolumab 7Leucovorin 7Gemcitabine 7Fluorouracil 7Doxorubicin 7aldesleukin 6Oxaliplatin 6Cisplatin 6liposomal doxorubicin 5Topotecan 5Taxes 5Irinotecan 5Interleukin-2 5olaparib 4atezolizumab 4Hyperthermic Intraperitoneal Chemotherapy 4Drug Therapy 4seribantumab 3fludarabine phosphate 3durvalumab 3dostarlimab 3dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasm Metastasis × CTLA-4 Antigen × Gynecologic × Clear all
NCT04840589 2026-05-13

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

National Cancer Institute (NCI)

Phase 1 Suspended
66 enrolled
Gynecologic

Neoplasm Metastasis, Ovarian Neoplasms

NCT02419495 2025-06-04

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Terminated
221 enrolled
BreastDermatologicGenitourinaryGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Ovarian Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡